Printer Friendly

SCHERING-PLOUGH AND CELLTECH IN AGREEMENT TO DEVELOP ANTIBODIES TO CYTOKINES

 MADISON, N.J., and SLOUGH, U.K., Jan. 7 /PRNewswire/ -- Schering- Plough Corporation (NYSE: SGP), on behalf of several of its affiliated companies, and Celltech Group p.l.c. today announced a collaboration and licensing agreement for developing and commercializing genetically engineered antibodies to selected cytokines (chemical messengers in the body).
 By blocking the activity of cytokines, anticytokines offer therapeutic potential in treating inflammatory diseases and immune disorders associated with organ transplants, juvenile onset diabetes and multiple sclerosis.
 Both companies will work on the design and process development of the antibodies. Schering-Plough will be responsible for taking drug candidates through preclinical testing and patient evaluation. Celltech will have co-promotion rights with Schering-Plough to resulting products in the European Community, and Schering-Plough will have exclusive commercialization rights in the rest of the world. Celltech will receive payments and royalties on the sale of products outside the European Community.
 Dr. Peter Fellner, chief executive of Celltech, commented, "The establishment of a platform of strategic alliances with major pharmaceutical companies for the clinical development and marketing of innovative products is an important factor in Celltech's development. Our agreement with Schering-Plough represents an important step in our progress toward becoming an integrated pharmaceutical company. The complementary skills of the two R&D groups means we should rapidly be able to advance a candidate for clinical testing."
 Dr. Frank Bullock, senior vice president of research operations, Schering-Plough Research Institute, said, "We are pleased to establish this collaborative effort with Celltech, as the company has considerable experience and technology in antibodies, ranging from discovery right through to production."
 Celltech is a leading European biotechnology company with unique skills in the design and development of monoclonal antibodies. Schering-Plough is a research-based company engaged in the discovery, development, manufacturing and marketing of pharmaceutical and health care products worldwide.
 -0- 1/7/93
 /CONTACT: Ronald Asinari of Schering-Plough, 201-822-7402, or Dr. Gwen Duthu of Celltech Group, (U.K.) 75-353-4655/
 (SGP)


CO: Schering-Plough Corporation; Celltech Group plc ST: New Jersey IN: MTC SU:

TS -- NY012 -- 2507 01/07/93 09:03 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 7, 1993
Words:342
Previous Article:THYMOSIN ALPHA 1 TO BE EVALUATED IN CLINICAL TRIAL IN MEXICO
Next Article:ISIS PUBLISHES NEW FINDINGS ON THE DESIGN OF ANTISENSE DRUGS
Topics:


Related Articles
SCHERING-PLOUGH AND SANDOZ PHARMA ANNOUNCE THAT CPMP RECOMMENDS APPROVAL 'LEUCOMAX' IN EUROPEAN COMMUNITY
ICN/SCHERING-PLOUGH LICENSING AGREEMENT FOR HEPATITIS C IN EFFECT FOLLOWING FEDERAL TRADE COMMISSION CLEARANCE
Schering-Plough and Genome Therapeutics Announce Alliance to Develop Antifungal Pharmaceutical Products
Phase III Trials Underway for Desloratadine.
Celltech Merger with Medeva Completed Creating one of the Largest European Biopharmaceutical Companies with Substantial US Operations.
Schering-Plough and NeoGenesis Announce Research Collaboration To Discover Small-Molecule Drugs.
Celltech and Maxygen Enter Into Antibody Collaboration.
Pharmacopeia forms new research collaboration with Schering Plough.
Schering-Plough Exercises Rights to Centocor's CNTO 148 Anti-TNF Agent.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters